Search Results

Imagine Pharma, a biotech company focused on advancing the commercialization of its novel IMG-1 polypeptide in Oral Delivery, Therapeutics, and Regenerative Medicine, announced that the West Virginia University Health System, which operates under the brand WVU Medicine, has awarded a contract to the Company to provide human clinical islet isolation services for patients undergoing a total pancreatectomy and autologous islet cell transplant.

Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, proudly announces the appointment of Virginia Savova, PhD as a strategic and scientific advisor.

Xenetic Biosciences, Inc. today announced it has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia (“UVA”) to advance the development of its systemic DNase program.

Empress Therapeutics today announced that Virginia Finnerty-Brooks has been appointed Chief Business Officer (CBO).

Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas, today announced it has entered into a drug development collaboration with the University of Virginia (UVA) to advance novel inhaled-drug candidates for treating bacterial infections in the lungs.

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the second clinical trial site in the Phase 1 Deltacel-01 trial evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with non-small cell lung cancer (NSCLC).

Fresenius Kabi announced today it has signed an agreement with Virginia Oncology Associates (VOA) under which VOA will purchase the Ivenix Infusion System to deliver medications for its patients.